Ciba Self-Medication president will be Zyma's Remo Denti, succeeding Peter Mayer.
This article was originally published in The Tan Sheet
Executive Summary
CIBA SELF-MEDICATION PRESIDENT WILL BE REMO DENTI, the current head of Ciba-Geigy Ltd.'s Zyma SA subsidiary headquartered in Nyon, Switzerland. Denti will succeed Peter Mayer, PhD, as president of U.S.-based Ciba Self-Medication and head of Self-Medication, North America, effective June 1. Ciba announced to employees on April 26 that Mayer was leaving the company due to "philosophical differences with regard to the management of the North America business."
|
CIBA SELF-MEDICATION PRESIDENT WILL BE REMO DENTI, the current head of Ciba-Geigy Ltd.'s Zyma SA subsidiary headquartered in Nyon, Switzerland. Denti will succeed Peter Mayer, PhD, as president of U.S.-based Ciba Self-Medication and head of Self-Medication, North America, effective June 1. Ciba announced to employees on April 26 that Mayer was leaving the company due to "philosophical differences with regard to the management of the North America business." Denti, a physician, has been managing director of Zyma for 10 years and with Ciba for approximately 30 years. He joined Ciba's pharmaceutical division in 1963 and held various positions including medical director, marketing director, and head of divisions in East-Africa, Canada and Argentina. He was a member of the management committee of Ciba's pharmaceuticals division in Basel, Switzerland from 1978 to 1984, when he joined Zyma. Zyma SA is the parent of a group of affiliated companies marketing nonprescription drugs in Europe and other markets outside North America. The group has annual sales in the region of SFr. 700 mil., or roughly $600 mil., and its leading brands include Otrivin nasal decongestants, Feniscil antihistamines, Importal laxatives and the Nicotinell smoking cessation product. Zyma has marketed Ciba's self-medication products since January 1992 and became a wholly owned subsidiary of Ciba-Geigy in 1991, when Ciba bought out the remainder of its stock. Peter Mayer has been president of Ciba Self-Medication since 1991. He joined the company as group VP-marketing for the OTC group -- then known as Ciba Consumer Pharmaceuticals -- in 1987. He held that position until he was named president. Two major acquisitions by the OTC group were undertaken while Mayer was at the helm. Ciba bought Fisons' North American OTC business, including the Desenex, Cruex, Allerest and Caldecort brands, in 1993 and the Rhone-Poulenc Rorer OTC brands, including Maalox, Perdiem and Ascriptin, earlier this year ("The Tan Sheet" Jan. 2, p. 3). Concurrent with his resignation from Ciba, Mayer gave up his position on the board of the Nonprescription Drug Manufacturers Association. He had been a board member since 1991 and also served for several years on the NDMA marketing committee. |